F-10POS: Oncolytics Biotech Withdraws Unsold Securities from Registration
Post-Effective Amendment to Registration Statement
Oncolytics Biotech Inc. is filing a post-effective amendment to deregister unsold securities from multiple previous F-10 registration statements.
Summary
- Oncolytics Biotech Inc. has filed a post-effective amendment to several F-10 registration statements.
- The purpose of this filing is to withdraw and deregister any unsold portions of securities that were previously registered.
- This action pertains to multiple registration statements filed between 2007 and 2024, covering various types of securities including units, common shares, subscription receipts, and warrants.
- The amendment specifically revises the effectiveness date and time for the registration statements to April 8, 2026, at 4:30 p.m. Eastern time.
- No other changes have been made to the registration statements themselves.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it indicates that previous capital raising efforts did not fully subscribe, suggesting potential challenges in market absorption for the company's securities.
Future Outlook
The filing does not contain forward-looking statements or guidance; it is solely an administrative amendment to deregister unsold securities.
Industry Context
StockSavvy.ai notes that this filing is a procedural step for Oncolytics Biotech, indicating that previous offerings of securities did not fully sell out. This is common for companies utilizing shelf registration statements and does not inherently reflect current operational performance or future prospects.
Stakeholder Impact
- Shareholders: This filing does not directly impact current shareholders as it pertains to unsold securities from past offerings. It may indirectly suggest market conditions or investor appetite for the company's securities at the time of previous offerings.
Next Steps
- The deregistration of unsold securities will be completed upon the effectiveness of this amendment on April 8, 2026.
Key Dates
| Date | Description |
|---|---|
| 2007-02-02 | Initial filing date for Registration Statement No. 333-140460. |
| 2007-02-08 | Initial filing date for Registration Statement No. 333-140529. |
| 2008-06-06 | Initial filing date for Registration Statement No. 333-151513. |
| 2010-06-02 | Initial filing date for Registration Statement No. 333-167250. |
| 2012-06-21 | Initial filing date for Registration Statement No. 333-182260. |
| 2014-07-25 | Initial filing date for Registration Statement No. 333-197633. |
| 2018-04-25 | Initial filing date for Registration Statement No. 333-224432. |
| 2020-06-08 | Initial filing date for Registration Statement No. 333-239025. |
| 2022-06-10 | Initial filing date for Registration Statement No. 333-265510. |
| 2024-07-25 | Initial filing date for Registration Statement No. 333-281009. |
| 2026-04-06 | Date of the current Post-Effective Amendment No. 2 filing. |
| 2026-04-08 | Designated effectiveness date and time for the amendment (April 8, 2026, at 4:30 p.m. Eastern time). |
Keywords
Oncolytics Biotech, SEC Filing, F-10 Registration Statement, Securities Deregistration, Post-Effective Amendment, Unsold Securities, Form F-10
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.